Revolution Medicines
NASDAQ:RVMDBiotechUnited States · Est. 2014
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
11
Indications↗
Distinct diseases across all programs
29
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 32
Phase 23
Phase 14
Preclinical5
By Therapeutic Area
top 1
Oncology
571%
R&D Momentum
54/100
Pipeline Velocity
27/100
Trial Completion Rate
100/100
Pipeline Concentration
59/100
Pipeline Freshness
79/100
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Recruiting
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Sep 16, 2026
Recruiting
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Sep 15, 2026
Recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
Sep 11, 2026
Recruiting
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
Sep 9, 2026
Recruiting
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Earlier
Sep 2, 2026TrialExpanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
Aug 28, 2026TrialRASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
Aug 26, 2026FDARasonque — RASONQUE
4 more events
Aug 21, 2026TrialA Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)
Aug 4, 2026TrialPhase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
Aug 4, 2026TrialA Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Jul 30, 2026TrialA Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Details
Company Info
Therapeutic Focus
OncologyOther
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology(5 drugs)
5
4
2
2
—
Oncology(5 drugs)
Unknown / Other(2 drugs)
—
—
2
—
—
Unknown / Other(2 drugs)
Regulatory
Regulatory Timeline
20261 event
FDAAug 26
Rasonque — RASONQUE
Application NDA220910 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)